Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
NCT ID: NCT05300048
Last Updated: 2025-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
34 participants
INTERVENTIONAL
2022-04-22
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
NCT01540253
Trial of PTK787/ZK 222584 Plus Paclitaxel
NCT00358163
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
NCT05037149
Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
NCT00940498
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
NCT01155453
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1a - Dose Modification without nab-paclitaxel
Subjects with any solid tumor will receive multiple doses of serabelisib administered orally and will consume Insulin Suppressing Diet for up to 12 months
Serabelisib
serabelisib administered orally
Insulin Suppressing Diet
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
Cohort 1b - Dose Modification with Nab-Paclitaxel
Subjects with endometrial cancer, ovarian clear cell or ovarian endometriod carcinoma will receive multiple doses of serabelisib administered orally and will consume Insulin Suppressing Diet for up to 12 months. In addition, these subjects will receive nab-paclitaxel intravenously weekly.
Serabelisib
serabelisib administered orally
Insulin Suppressing Diet
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
Nab paclitaxel
nab-paclitaxel administered intravenously weekly
Cohort 2 - Expansion Colorectal Cancer
Subjects will receive dose of serabelisib as determined from Cohort 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months
Serabelisib
serabelisib administered orally
Insulin Suppressing Diet
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
Cohort 3 - Expansion Endometrial Cancer
Subjects will receive dose of serabelisib as determined from Cohort 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months. If results from Cohort 1b show a favorable risk-benefit ratio, nab-paclitaxel will be administered intravenously weekly.
Serabelisib
serabelisib administered orally
Insulin Suppressing Diet
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
Nab paclitaxel
nab-paclitaxel administered intravenously weekly
Cohort 4 - Expansion Ovarian Clear Cell or Ovarian Endometrioid Carcinoma
Subjects will receive dose of serabelisib as determined from Cohorts 1a and 1b, and will consume Insulin Suppressing Diet for up to 12 months. If results from Cohort 1b show a favorable risk-benefit ratio, nab-paclitaxel will be administered intravenously weekly.
Serabelisib
serabelisib administered orally
Insulin Suppressing Diet
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
Nab paclitaxel
nab-paclitaxel administered intravenously weekly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serabelisib
serabelisib administered orally
Insulin Suppressing Diet
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
Nab paclitaxel
nab-paclitaxel administered intravenously weekly
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥18 at Visit -1 (screening).
3. Histologically or cytologically confirmed recurrent solid tumors.
1. Cohort 1a: any extracranial solid tumor (may include EC, ovarian clear cell, or ovarian endometrioid carcinoma if subject is not eligible for nab-paclitaxel in Cohort
1b)
2. Cohort 1b: either recurrent or persistent endometrial adenocarcinoma (EC) with the following histologic epithelial cell types: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma, and carcinosarcoma or; ovarian cancer (OC) with the primary tumor having ≥ 50% clear cell histomorphology or ovarian clear cell or ovarian endometrioid carcinoma.
3. Cohort 2: adenocarcinoma of the colon or rectum.
4. Cohort 3: recurrent or persistent endometrial adenocarcinoma with the following histologic epithelial cell types as described for Cohort 1b
5. Cohort 4: OC primary tumor carcinomas as described for Cohort 1b
4. Tumor must harbor an activating mutation in the PIK3CA gene with or without PTEN loss, either previously documented or determined during screening.
5. Fresh or archival tumor biopsy with sufficient material to be sent to the designated laboratory for PD analyses. For subjects who consent to future research, an additional 5 slides from a surgical specimen or biopsy is required.
6. Cohort 1a - Dose Modification (subjects with any solid tumor): failed, were intolerant of, or ineligible for no more than three prior lines of therapy (LOT) for advanced/metastatic disease or refused SOC therapy.
7. For all cohorts, in the unlikely scenario that a subject refused all available SOC they may proceed with trial. These subjects would be regarded as having 0 prior LOT.
8. Cohorts 1b, 2, 3, and 4 - failed, were intolerant of, ineligible for, or have refused SOC therapy for advanced/metastatic disease (AJCC stage III and IV) and:
1. Cohort 2 (subjects with colorectal cancer): Have failed no more than two prior LOT for metastatic CRC.
2. Cohort 1b, and Cohort 3 (subjects with EC): Have no more than three prior chemotherapeutic regimens for management of endometrial carcinoma (neo-adjuvant and/or adjuvant chemotherapy will be counted as one prior LOT). Prior hormonal therapy will not count as a systemic regimen.
3. Cohort 1b, and Cohort 4 (subjects with clear cell or endometrioid OC): Subjects must have had no more than three prior chemotherapeutic regimens for management of ovarian carcinoma. Prior hormonal therapy will not count as a systemic regimen.
9. Life expectancy of at least 3 months.
10. At least one measurable lesion (as defined by Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1).
11. ECOG PS of 0 to 1.
12. Adequate organ function
1. Absolute neutrophil count (ANC) ≥1.0 × 10\^9/L or ≥1.5 x 10\^9/L if planned to be treated with nab-paclitaxel, platelet count ≥75 × 10\^9/L, and hemoglobin ≥8.5 gm/dL (may be transfused to reach this hemoglobin level unless due to blood loss).
2. Liver transaminases (AST and ALT) ≤2.5 × upper limit of normal (ULN) (\<5 × ULN if liver metastases are present), and total bilirubin ≤1.5 × ULN (\<3 x ULN if subject has Gilbert Syndrome).
3. INR ≤1.5 x ULN unless subject is on anticoagulants that would affect the INR, then INR must be in the desired therapeutic range as judged by the Investigator.
4. Albumin level ≥3.0 mg/dL or ≥ the lower limit of normal.
5. Renal: Serum creatinine ≤2 x ULN
13. Ability to take PO medication, be willing to adhere to study procedures and Study Intervention administration, and receive, consume, and comply with Study ISD.
14. For women of child-bearing potential, a negative serum pregnancy test collected at screening (Visit-1) and negative urine pregnancy test collected at baseline (Visit-1) and use of physician-approved method of birth control from the time of the pregnancy test performed at screening to 90 days following the last administration of Study Drug or, if applicable, 6 months following the last administration of nab-paclitaxel.
15. Male subjects must be surgically sterile or must agree to use physician-approved contraception during the study and for 90 days following the last administration of Study Drug.
Exclusion Criteria
2. Has had serabelisib, alpelisib, or other PI3K inhibitor.
3. Leptomeningeal disease and symptomatic or untreated brain metastases.
4. Diagnosis of, or requiring treatment for, another malignancy within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 90 days prior to the first dose of Study Drug).
5. Is less than 21 days from therapeutic radiation or chemotherapy prior to the first day of dosing with Study Drug and has not recovered to Grade ≤ 1 from all clinically significant toxicities related to prior therapies.
6. For subjects receiving nitrosoureas or mitomycin C, the subject is \< 6 weeks from last dose. For monoclonal antibody therapy, the subject is \< 1 half-life or \<4 weeks from the last dose.
7. Chronic, systemically administered glucocorticoids in doses equivalent to \>5 mg prednisone daily. Replacement corticosteroids for adrenal insufficiency are permitted.
8. Diabetes mellitus requiring insulin or insulin secretagogue therapy.
9. Poorly controlled diabetes mellitus defined as glycosylated hemoglobin A1c (HbA1c) \>7.5% or fasting blood sugar \>160 mg/ dL.
10. Known impaired cardiac function or clinically significant cardiac disease.
11. QTcF interval \>470 msec found at screening.
12. Myocardial infarction, cardiac stent placement, or unstable angina within 6 months before the first administration of Study Drug.
13. Have clinically significant peripheral vascular disease.
14. Manifestations of malabsorption
15. Other clinically significant comorbidities.
16. Pregnant (positive serum pregnancy test), planning to become pregnant during the study, or breastfeeding/planning to breastfeed during the study.
17. Have taken strong CYP3A4 inducers/inhibitors within 7 days before the first administration of serabelisib or have conditions that require the concomitant use of CYP3A4 inducers/inhibitors.
18. Untreated or poorly controlled, gastro-esophageal reflux disease.
19. Have taken histamine-H2 receptor antagonists within 12 hours before the first administration of serabelisib.
20. Have taken PPI within 7 days or 5 half-lives (whichever is the shorter duration) before the first administration of serabelisib or are anticipated to need PPI during the study.
21. Have taken neutralizing antacids within 4 hours before the first administration of serabelisib or are anticipated to need frequent antacid use during the study.
22. Subjects with poorly controlled human immunodeficiency virus, hepatitis B virus, and/or hepatitis C virus infections.
23. Known allergies to nab-paclitaxel or excipients, serabelisib or excipients or the ISD
24. Severe, uncontrolled gout.
25. A BMI \<18.5 kg/m2, or serious or refractive cachexia or anorexia that, in the Investigator's opinion, realistically prohibits subjects from having energy or appetite sufficient to reliably engage in a strict ISD regimen for an extended time.
26. Any condition that renders the subject unable to satisfactorily chew, swallow, digest, or tolerate (i.e., persistent diarrhea) the majority of foods and liquids of the Study ISD.
27. History of severe nephrolithiasis requiring urologic intervention.
28. Participation in a diet or weight loss plan within 10 days prior to the first administration of Study Drug.
29. Severe constipation or condition where exacerbation of constipation is not advisable (eg, small bowel obstruction history).
30. History of anaphylaxis from food allergy or other disease state requiring avoidance of a particular food, such as celiac disease.
31. Diagnosed eating disorder in the past 10 years.
32. Unwilling to take a non-vegan or non-vegetarian diet.
33. Peripheral neuropathy ≥ CTC Grade 2
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Faeth Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vicky Makker
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Pacific Cancer Specialists
Anaheim, California, United States
Valkyrie Clinical Trials
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Community Health Network, Inc.
Indianapolis, Indiana, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
New Jersey Cancer Care, PA
Belleville, New Jersey, United States
Englewood Health
Englewood, New Jersey, United States
Northwell Health
Lake Success, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
East Carolina University
Greenville, North Carolina, United States
University of Pennsylvania Health System, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
Baptist Hospitals of Southeast Texas
Beaumont, Texas, United States
Oncology Consultants, PA
Houston, Texas, United States
Lumi Research
Kingwood, Texas, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SER-ISD1-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.